ReviewIndian heart journal
ACEI-induced cough: A review of current evidence and its practical implications for optimal CV risk reduction.
Review in Indian heart journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Adverse Effects of Angiotensin-Converting Enzyme Inhibitors in Humans: A Systematic Review and Meta-Analysis of 378 Randomized Controlled Trials.International journal of environmental research and public health · 2022Pooled it
- Comparison of two single-pill dual combination antihypertensive therapies in Chinese patients: a randomized, controlled trial.BMC medicine · 2024Trial
- Clinical analyses of angiotensin-converting enzyme inhibitor users presenting with cough to a chest diseases outpatient clinic: A single-center retrospective study.The Journal of international medical research · 2026Article
- Large-Scale Signal Detection and Personalized Risk Prediction for Cardiovascular Drug Adverse Reactions in Elderly Patients: Real-World Evidence from Western China.Cardiovascular toxicology · 2026Article
- Budesonide/glycopyrronium/formoterol fumarate co-suspension metered dose inhaler relieves cough after lobectomy: a randomized controlled study.Translational lung cancer research · 2025Article
- The role of single-pill ACE inhibitor/ccb combination for hypertension: an Algerian view via the nominal group technique.Future cardiology · 2025Review
- Pharmacogenomic biomarkers of ACE inhibitor-induced cough in a multi-ethnic UAE cohort.Frontiers in pharmacology · 2025Article
- Angiotensin-(1-7) and Central Control of Cardiometabolic Outcomes: Implications for Obesity Hypertension.International journal of molecular sciences · 2024Review
- Pediatric Chronic Heart Failure: Age-Specific Considerations of Medical Therapy.Physiological research · 2024Review
- Pharmacogenetic study of CES1 gene and enalapril efficacy.Journal of applied genetics · 2024Review
- Considering Adverse Effects of Common Antihypertensive Medications in the ED.Current hypertension reports · 2024Review
- Management of Hypertension in the Asia-Pacific Region: A Structured Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Review
- An Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS) Method for Qualifying DAPB in Rat Plasma and Application to Pharmacokinetic Studies.Molecules (Basel, Switzerland) · 2024Article
- Exploring the scientific underpinnings of investigating safety signals: analytical insights in deciphering drug safety evidence.Frontiers in drug safety and regulation · 2024Article
- Case Report: Angiotensin converting enzyme inhibitors vs. angiotensin receptor blockers in the management of chronic hypertension: a case of lisinopril-induced rhinorrhea.Frontiers in allergy · 2024Article
- Traditional Therapeutics and Potential Epidrugs for CVD: Why Not Both?Life (Basel, Switzerland) · 2023Review
- Drug-Related Problems and Pharmacists' Interventions in Hypertensive Outpatients: A Multicenter Prospective Study in 3 Vietnamese Hospitals.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2023Article
- Review
- Practice of pharmaceutical care by community pharmacists in response to self-medication request for a cough: a simulated client study.BMC health services research · 2023Article
- Is It Still Relevant to Discover New ACE Inhibitors from Natural Products? YES, but Only with Comprehensive Approaches to Address the Patients' Real Problems: Chronic Dry Cough and Angioedema.Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cough is one of the common adverse effects in patients receiving angiotensin-converting enzyme inhibitors (ACEIs). This review presents the current evidence on incidence and mechanisms of cough associated with ACEIs use, and proposes a practical approach for managing the same for optimal cardiovascular (CV) risk reduction. The incidence of dry cough in patients receiving ACEIs vary among individual ACEIs, and is the lowest with perindopril. Cough is thought to originate from multiple mechanisms, bradykinin theory is the most commonly appealed hypothesis. The strategies for optimal management could be temporarily discontinuation of ACEI upon a reported incidence of cough and reintroduction after its remission. However, studies have reported disappearance of cough despite continuing treatment. Another important approach could be adding calcium channel blockers to ACEIs. Switching to alternative drugs such as angiotensin receptor blockers should be suggested in case intolerable symptoms recur and after exclusion of all other possible causes of cough.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.